Pharmaceutical Investing MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
Pharmaceutical Investing MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 in Alcohol Use Disorder and Withdrawal
Pharmaceutical Investing Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock
Pharmaceutical Investing MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre
MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
Pharmaceutical Investing MediciNova Announces Closing of Underwritten Public Offering of Common Stock
